ADPKD Guideline published
A new Renal Association Clinical Practice Guideline has been published on Monitoring children and young people with, or at risk of developing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Expressions of interest for new RRT commentary
We are seeking expressions of interest for Renal Association Members to write a commentary on the NICE Renal Replacement Therapy and Conservative Management Guideline (published in October 2018).
This is an important document for the Renal Association and we hope that members with relevant expertise will apply.
It will replace the current guideline on “planning, initiation and withdrawal of RRT”, which is due for renewal.
It will contain RA recommendations, stating where they agree or differ from NICE, and also audit measures.
The recently published Commentary on the KDIGO Guideline on the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD shows the format for the type of commentary the RA aims to produce when a full guideline on a topic has been written by NICE or KDIGO.
To apply, please send a statement of no more than one side of A4, explaining why you would like to do this. Please also send a completed Conflict of Interest Form.
Please send any expressions of interest to Melanie.Dillon@renalregistry.nhs.uk by Friday 11th January 2019.
Survey on RA Guideline on renal care in pregnancy
We would like your feedback on the first UK guideline on renal disease in pregnancy. The aim of the guideline is to improve and standardise the care of women with CKD who are planning a pregnancy, pregnant, or in the postpartum period.
The guideline has 97 statements that address the care of women with CKD prior to, during, and following pregnancy. These statements are divided in sections including structure of care, medication, pre-pregnancy and pregnancy care, renal transplantation, dialysis, lupus, diabetes and congenital abnormalities of the kidney and urinary tract.
Via this survey (www.surveymonkey.co.uk/r/PregnancyCKD) your comments will inform the on going development of the guideline prior to publication in 2019.
The survey is open to both patients and clinicians.
We would be grateful for your participation by Friday 14th December.
If you have any queries, please contact firstname.lastname@example.org